JP2024545420A5 - - Google Patents
Info
- Publication number
- JP2024545420A5 JP2024545420A5 JP2024532444A JP2024532444A JP2024545420A5 JP 2024545420 A5 JP2024545420 A5 JP 2024545420A5 JP 2024532444 A JP2024532444 A JP 2024532444A JP 2024532444 A JP2024532444 A JP 2024532444A JP 2024545420 A5 JP2024545420 A5 JP 2024545420A5
- Authority
- JP
- Japan
- Prior art keywords
- deletion
- amino acid
- cov
- glycoprotein
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284497P | 2021-11-30 | 2021-11-30 | |
| US63/284,497 | 2021-11-30 | ||
| US202163292120P | 2021-12-21 | 2021-12-21 | |
| US63/292,120 | 2021-12-21 | ||
| US202163293519P | 2021-12-23 | 2021-12-23 | |
| US63/293,519 | 2021-12-23 | ||
| US202263332530P | 2022-04-19 | 2022-04-19 | |
| US63/332,530 | 2022-04-19 | ||
| US202263367678P | 2022-07-05 | 2022-07-05 | |
| US63/367,678 | 2022-07-05 | ||
| PCT/US2022/080700 WO2023102448A2 (en) | 2021-11-30 | 2022-11-30 | Coronavirus vaccine formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545420A JP2024545420A (ja) | 2024-12-06 |
| JP2024545420A5 true JP2024545420A5 (enExample) | 2025-11-13 |
Family
ID=86613115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532444A Pending JP2024545420A (ja) | 2021-11-30 | 2022-11-30 | コロナウイルスワクチン製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250025549A1 (enExample) |
| EP (1) | EP4440613A4 (enExample) |
| JP (1) | JP2024545420A (enExample) |
| KR (1) | KR20240125935A (enExample) |
| AU (1) | AU2022399829A1 (enExample) |
| CA (1) | CA3241118A1 (enExample) |
| IL (1) | IL313254A (enExample) |
| MX (1) | MX2024006589A (enExample) |
| TW (1) | TW202332685A (enExample) |
| WO (1) | WO2023102448A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| EP4608442A1 (en) * | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| US20250144200A1 (en) | 2023-11-06 | 2025-05-08 | Novavax, Inc. | Intranasal immunogenic compositions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230070886A1 (en) * | 2020-01-27 | 2023-03-09 | Novavax, Inc. | Coronavirus vaccine formulations |
| JP2023511633A (ja) * | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスｒｎａワクチン |
| JP2023512519A (ja) * | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| AR128082A1 (es) * | 2021-12-23 | 2024-03-20 | Novavax Inc | ANTICUERPOS CONTRA LA ESPÍCULA (S) DEL SARS-CoV-2 Y SU USO EN EL TRATAMIENTO DE COVID-19 |
| CN119836572A (zh) * | 2022-07-26 | 2025-04-15 | 诺瓦瓦克斯股份有限公司 | 用于评价疫苗免疫原性的ace2抑制测定 |
| AU2023315949A1 (en) * | 2022-07-26 | 2025-02-20 | Novavax, Inc. | Pseudovirus based neutralization assay for evaluating vaccine immunogenicity |
-
2022
- 2022-11-30 US US18/715,010 patent/US20250025549A1/en active Pending
- 2022-11-30 IL IL313254A patent/IL313254A/en unknown
- 2022-11-30 WO PCT/US2022/080700 patent/WO2023102448A2/en not_active Ceased
- 2022-11-30 KR KR1020247021797A patent/KR20240125935A/ko active Pending
- 2022-11-30 MX MX2024006589A patent/MX2024006589A/es unknown
- 2022-11-30 AU AU2022399829A patent/AU2022399829A1/en active Pending
- 2022-11-30 EP EP22902377.5A patent/EP4440613A4/en active Pending
- 2022-11-30 JP JP2024532444A patent/JP2024545420A/ja active Pending
- 2022-11-30 TW TW111145944A patent/TW202332685A/zh unknown
- 2022-11-30 CA CA3241118A patent/CA3241118A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024545420A5 (enExample) | ||
| US9951113B2 (en) | Lectin compositions and methods for modulating an immune response to an antigen | |
| JP2026026092A5 (enExample) | ||
| JP2010500399A5 (enExample) | ||
| US9339536B2 (en) | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses | |
| JP2023512648A5 (enExample) | ||
| CA2496384C (en) | Lectin compositions and methods for modulating an immune response to an antigen | |
| US7629440B2 (en) | Lectin compositions and methods for modulating an immune response to an antigen | |
| JP2020023567A5 (enExample) | ||
| RU2018111760A (ru) | Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью | |
| US20010026798A1 (en) | Methods of enhancing activity of vaccines and vaccine compositions | |
| WO2019092002A1 (en) | Pharmaceutical compositions for treatment or prevention of viral infections | |
| CN113226364A (zh) | 组合物和方法 | |
| JP2021501761A (ja) | ネコ白血病ウイルスワクチン | |
| JP2023542297A5 (enExample) | ||
| Wang et al. | Embryonic stem cells attenuate viral myocarditis in murine model | |
| US20220275346A1 (en) | Hantavirus antigenic composition | |
| JPWO2016059911A1 (ja) | マラリアワクチン | |
| CN102740872A (zh) | 用于在老年人中提供保护性免疫的方法和组合物 | |
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| JP4578973B2 (ja) | 免疫刺激のためのｉｈｎｖｇ蛋白質 | |
| JP2024523329A5 (enExample) | ||
| CA2183260A1 (en) | Prolactin as a vaccine adjuvant | |
| JP2024511356A5 (enExample) | ||
| KR20210128517A (ko) | 변형된 인터루킨-7 단백질 및 이의 용도 |